Kellogg Eye Center at University of Michigan

Ann Arbor, Michigan 48105

0 studies enrolling now · 3 studies all time

What they study most

Graves' Orbitopathy, Thyroid Associated Ophthalmopathies, Thyroid Eye Disease, Thyroid-Associated Ophthalmopathy

Studies at this site

• Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease — Completed
• Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study — Completed
• Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study — Completed